COMMUNIQUÉS West-GlobeNewswire

RadNet Names Four Leaders to Expanded Executive Roles
07/01/2026
Bench of veteran leaders elevated to drive RadNet’s continued growth and innovation LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective [...]
ExamWorks Announces Strategic Leadership Transition Plan to Further Accelerate Long-Term Growth
07/01/2026
ATLANTA, GA, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ExamWorks Group (“ExamWorks”), a leading global provider of medical claims management solutions, including independent medical examinations, peer reviews, record retrieval [...]
RadNet Expands to Southwest Florida with Acquisition of Radiology Regional
07/01/2026
Purchase of 13 imaging centers brings cutting-edge diagnostic technology to one of Florida’s fastest-growing regions. LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in [...]
Curium’s Investigational New Drug Application Accepted by Center for Drug Evaluation in China
07/01/2026
Curium’s Investigational New Drug (IND) application for 177 Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer (mCRPC), has been accepted by the Centre for Drug [...]
Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance
07/01/2026
2026 Guidance Represents Year-Over-Year Increase of 13% in Revenues and 23% in Adjusted EBITDA Based on Mid-Point of 2025 Annual Guidance 2026 Annual Guidance is Based Solely on Continued Organic Growth Company [...]
Avance Clinical Strengthens Global Oncology Offering with Acquisition of U.S.-Based LumaBridge and Establishes New Oncology Center of Excellence
07/01/2026
ADELAIDE, Australia, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, a global contract research organization focused on accelerating clinical development for biotech sponsors, today announced the acquisition of [...]
Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism
07/01/2026
Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications Company plans to meet with FDA to align on path forward for congenital HI [...]
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
07/01/2026
U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter of 2026 On [...]
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
07/01/2026
BETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
07/01/2026
In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated rapid and [...]
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®
07/01/2026
Company remains focused on potential approval and launch of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE [...]
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs
07/01/2026
BBO-8520 monotherapy in patients with KRAS G12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients eligible for 6-month [...]
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
07/01/2026
- Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations - - Program will be launched in parts of Eurasia, Central and Southeast Europe, Israel, the [...]
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
07/01/2026
– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 – – Phase 3 DME [...]
Frontier Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
BOSTON and SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and [...]
JJP Biologics Announces Positive Top-Line Phase I Trial Results of JJP-1212, its anti-CD89 antagonist
07/01/2026
Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the program Supports the feasibility of intravenous and subcutaneous dosing regimens in upcoming clinical [...]
Kraig Biocraft Laboratories Takes Possession of Three Strategic Mulberry Fields Advancing Massive Spider Silk Production Ramp-Up
07/01/2026
ANN ARBOR, Mich., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or “Kraig’s”), a world leader in spider silk technology*, today announced that it has [...]
Glucose Health, Inc. Board Members Confirm Participation in Preferred Share Conversion at 85% Premium to Market and Introduce New Revenue Growth Strategy
07/01/2026
BENTONVILLE, Ark., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC), a consumer-health company specializing in soluble-fiber nutrition products for metabolic support, today confirmed that all members [...]
BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™
07/01/2026
New Premera Blue Cross Blue Shield® policy extends to both adolescent and adult depression patients BURLINGTON, Mass. and JERUSALEM, Jan. 07, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay [...]

Pages